Case: Patents/Obviousness (P.T.A.B.)

The Patent Trial and Appeal Board determined that challenged claims of Bausch Health Ireland Limited’s patent that relates to the therapeutic use of guanylate cyclase receptor agonists as a means for enhancing the intracellular production of cGMP aren’t unpatentable as obvious over prior art, in an inter partes review by MSN Laboratories Private Ltd. and MSN Pharmaceuticals Inc. The board said that the challenged claims aren’t obvious over various combinations of prior art, including prior art titled “Uroguanylin Treatment Suppresses Polyp Formation in the ApcMin/+ Mouse and Induces Apoptosis in Human Colon Adenocarcinoma Cells via Cyclic GMP,” “Synthesis, biological activity ...